DKK1 as a novel target for myeloma immunotherapy

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 756-758

  Qian, Jianfei ^a   Yi, Qing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Dickkopf 1; DNA; Immunotherapy; Multiple myeloma; Vaccine

Indexed keywords

CD134 ANTIGEN; DEFENSIN; DEFENSIN 2; DICKKOPF 1 PROTEIN; DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CPG ISLAND; CROSS PRESENTATION; DENDRITIC CELL; DRUG EFFICACY; MYELOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84886780359     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19655     Document Type: Article

References (10)

1. Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000; 108:805-16; PMID:10792287; http://dx.doi.org/10.1046/j.1365-2141.2000.01958.x
2. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998; 91:2459-66; PMID:9516146
3. Yi Q, Desikan R, Barlogie B, Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 2002; 117:297-305; PMID:11972511; http://dx.doi.org/10.1046/j.1365-2141.2002.03411.x
4. Yi Q. Dendritic cell-based immunotherapy in multiple myeloma. Leuk Lymphoma 2003; 44: 2031-8; PMID:14959845; http://dx.doi.org/10.1080/1042819031000116599
5. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. [see comment]. N Engl J Med 2003; 349:2483-94; PMID:14695408; http://dx.doi.org/10.1056/NEJMoa030847
6. Krupnik VE, Sharp JD, Jiang C, Robison K, Chickering TW, Amaravadi L, et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999; 238:301-13; PMID:10570958; http://dx.doi.org/10.1016/S0378-1119(99)00365-0
7. Yaccoby S, Ling W, Saha R, Zhan F, Walker R, Tricot G, et al. Inhibition of DKK1 activity is associated with increased osteoblast numbers and bone formation, reduced osteoclast activity and inhibtion of tumor growth in the SCID-rab model for primary myeloma. Blood 2005; 106:189a.
8. Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 2007; 110:1587-94; PMID:17515399; http://dx.doi.org/10.1182/blood-2007-03-082529
9. Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, et al. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 2012; 119:161-9; PMID:22049519; http://dx.doi.org/10.1182/blood- 2011-07-368472
10. Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, et al. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood 2009; 114:3880-9; PMID: 19654406; http://dx.doi.org/10.1182/blood-2009-06-227355